Urinary NNN assesement

PreclinicalBiologic

AAssistance Publique - Hôpitaux de Paris

Urinary NNN assesement is one of 22 biologic programs targeting CAR. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CARUnknown status

CARPreclinical

Unknown status

Competition

Competitive Landscape

36 competitors in CAR

#DrugCompanyPhaseTrials

Isopto Carpine

AAdvanz Pharma

Phase 3

3 2

Floxin

WWim Janssens

Phase 3

1 3

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 4

Pelacarsen

Novartis

Phase 3

1 5

L-Carnitine

IIperboreal Pharma Srl

Phase 3

1 6

Tegretol

Novartis

Phase 1

10 7

Tylenol

KKenvue Brands

Phase 2

1 8

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 9

Diamox

Teva

Phase 1

2 10

Trileptal

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

CAR1 trial

Determination of Carcinogens Nicotine in Electronic Cigarettes Users

Unknown status·AAssistance Publique - Hôpitaux de Paris·N/A·NCT02897401·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Urinary NNN assesement. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Urinary NNN assesement compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Urinary NNN assesement. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: AAssistance Publique - Hôpitaux de Paris

Urinary NNN assesement

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

CAR1 trial

References

Drug Info

Quick Facts

Related News